Navigation Links
CryoLife to Present at Sidoti's 13th Annual New York Emerging Growth Institutional Forum

ATLANTA, March 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 13th Annual New York Emerging Growth Institutional Forum at The Grand Hyatt Hotel on Wednesday, March 25, 2009.

D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present a corporate overview at 2:05 p.m. Eastern Time.

A copy of CryoLife's slide presentation will be posted the day of the presentation on the Investor Relations page of

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France, and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

For additional information about the Company, visit CryoLife's Web Site:

    Media Contacts:

    D. Ashley Lee                                          Katie Brazel
    Executive Vice President, Chief Financial Officer and  Fleishman Hillard
    Chief Operating Officer                                Phone: 404-739-0150
    Phone: 770-419-3355

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
2. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
3. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
4. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
5. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
6. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
7. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
8. CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
9. CryoLife to Present at UBS Global Life Sciences Conference
10. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
11. CryoLife Announces Management Promotions
Post Your Comments:
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):